MORRISVILLE, N.C. – May 30, 2024 – Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant enhancement to its services with a new 4-week project turnaround time for Global Discovery Panel projects up to 2,000 samples, specifically tailored to meet the needs of commercial markets. This announcement comes as a strategic addition to Metabolon’s recently launched spectral data files and bioinformatics platform offerings, reinforcing the company’s commitment to providing the highest quality and most comprehensive metabolomics solutions in the industry for multiomic research.
The accelerated project turnaround time is a direct response to the demands of commercial pharmaceutical customers who require timely and actionable insights to drive their research and development efforts. This includes analysis for biological fluids, such as plasma, urine, and serum. With this new initiative, Metabolon aims to empower commercial clients with faster access to metabolomics data and insights, enabling quicker decision-making and more efficient development pipelines.
“Our focus has always been on delivering unparalleled value to our customers, and this new 4-week project turnaround time is another step toward achieving that goal,” said Ro Hastie, CEO of Metabolon. “Metabolomics plays a crucial role in the multiomics space, providing essential and unique insights into biological processes and pathways that are vital for understanding disease mechanisms, identifying biomarkers, and developing targeted therapies. With Metabolon’s industry-leading expertise, highest quality standards, and largest library of metabolites, clients can trust the accuracy, reliability, and efficiency of our services.”
To learn more about how Metabolon deciphers thousands of discrete chemical signals to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/.
